Back

Validation of the HFA-ICOS risk assessment tool with real-world data from a prospective cohort of breast cancer patients in treatment with anthracyclines and trastuzumab

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardiomyopathy in cancer patients: prevalence, risk assessment, imaging, and prevention Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speakers

Photo
Doctor Enrique Canedo Guerra

Tlalpan (Mexico)

Photo
Doctor Nilda Espinola-Zavaleta

National Institute of Cardiology Ignacio Chavez, Mexico City (Mexico)

5 More presentations in this session

Presentation thumbnail
Prospective screening and proposed treatment algorithm for immune checkpoint inhibitor induced myositis in neoadjuvant-treated rectal cancer patients: data from the phase II CHINOREC trial
Doctor R. Zirnbauer (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Cardioprotective role of statins in breast cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis
Doctor S. Lingamsetty (Khammam, IN)
Abstract Slides Video
Presentation thumbnail
Anthracycline-induced arterial toxicity: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography
Doctor S. Rankin (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Comparison of two anthracycline regimens for treatment of breast cancer and the incidence of cardiac injury
Doctor N. Osataphan (Chiang Mai, TH)
Abstract Slides Video
Presentation thumbnail
Incidence, definitions and outcomes of anthracycline induced subclinical and clinical left ventricular dysfunction: a systematic review and meta-analysis
Doctor N. Farooqui (Rochester, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiomyopathy in cancer patients: prevalence, risk assessment, imaging, and prevention

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Cancer therapy-related cardiovascular toxicity: what is the accuracy of baseline cardiovascular risk stratification in the prediction of its occurrence?
thumbnail
Congress Presentation
Cardiotoxicity risk assessment using HFA-ICOS score: a cross-sectional analysis of patients with breast cancer undergoing chemotherapy or anti-HER2 therapies in a tertiary care center
thumbnail
Congress Presentation
Current challenges in risk stratification of cancer therapy-related cardiovascular toxicity

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources